McKesson Corporation $MCK Stock Position Raised by Lansforsakringar Fondforvaltning AB publ

Lansforsakringar Fondforvaltning AB publ increased its holdings in shares of McKesson Corporation (NYSE:MCK) by 3.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,304 shares of the company’s stock after acquiring an additional 1,232 shares during the quarter. Lansforsakringar Fondforvaltning AB publ’s holdings in McKesson were worth $35,743,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Cullen Investment Group LTD. increased its position in McKesson by 550.4% in the 4th quarter. Cullen Investment Group LTD. now owns 4,670 shares of the company’s stock valued at $3,811,000 after acquiring an additional 3,952 shares during the period. Pensionfund Sabic acquired a new position in McKesson during the 4th quarter worth $1,887,000. Achmea Investment Management B.V. grew its stake in shares of McKesson by 7.5% in the third quarter. Achmea Investment Management B.V. now owns 61,287 shares of the company’s stock worth $47,347,000 after purchasing an additional 4,260 shares in the last quarter. Investment Research Partners LLC bought a new position in shares of McKesson in the third quarter worth $1,303,000. Finally, Horizon Investments LLC increased its holdings in shares of McKesson by 125.4% during the fourth quarter. Horizon Investments LLC now owns 8,679 shares of the company’s stock valued at $7,119,000 after purchasing an additional 4,828 shares during the period. Institutional investors own 85.07% of the company’s stock.

McKesson Stock Down 1.9%

Shares of MCK stock opened at $749.37 on Tuesday. The stock has a 50-day simple moving average of $775.18 and a 200 day simple moving average of $840.27. McKesson Corporation has a fifty-two week low of $637.00 and a fifty-two week high of $999.00. The stock has a market capitalization of $87.74 billion, a P/E ratio of 19.48, a P/E/G ratio of 1.26 and a beta of 0.31.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Thursday, May 7th. The company reported $11.69 EPS for the quarter, topping the consensus estimate of $11.56 by $0.13. McKesson had a net margin of 1.18% and a negative return on equity of 345.35%. The firm had revenue of $96.30 billion for the quarter, compared to analysts’ expectations of $101.35 billion. During the same period in the previous year, the business earned $10.12 earnings per share. McKesson’s revenue for the quarter was up 6.0% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. On average, sell-side analysts anticipate that McKesson Corporation will post 44.28 earnings per share for the current year.

McKesson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Investors of record on Monday, June 1st will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 1st. This represents a $3.28 annualized dividend and a yield of 0.4%. McKesson’s dividend payout ratio is currently 8.53%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on MCK shares. Leerink Partners restated an “outperform” rating and set a $1,085.00 price objective on shares of McKesson in a research note on Thursday, March 5th. UBS Group raised their target price on shares of McKesson from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Barclays dropped their price target on shares of McKesson from $1,050.00 to $925.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 10th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $875.00 price target on shares of McKesson in a research note on Friday, May 8th. Finally, Wells Fargo & Company lowered their price objective on shares of McKesson from $925.00 to $812.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Fourteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, McKesson currently has a consensus rating of “Moderate Buy” and a consensus price target of $960.53.

Insider Buying and Selling at McKesson

In other McKesson news, CEO Brian S. Tyler sold 8,463 shares of McKesson stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $775.13, for a total value of $6,559,925.19. Following the transaction, the chief executive officer owned 14,382 shares in the company, valued at approximately $11,147,919.66. The trade was a 37.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Napoleon B. Rutledge, Jr. sold 133 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $764.00, for a total value of $101,612.00. Following the sale, the chief accounting officer owned 632 shares of the company’s stock, valued at $482,848. This trade represents a 17.39% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 20,285 shares of company stock valued at $15,546,137. 0.06% of the stock is currently owned by corporate insiders.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.